Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting

DATE: 23 Mar 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting ISB 1442 is…

Continue ReadingIchnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting

Ichnos Sciences Announces Selection of Trispecific Antibody ISB 2001 as Next Clinical Candidate for Relapsed/Refractory Multiple Myeloma

DATE: 09 May 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Announces Selection of Trispecific Antibody ISB 2001 as Next Clinical Candidate for Relapsed/Refractory Multiple Myeloma First TREAT™ Trispecific Antibody Targeting BCMA and…

Continue ReadingIchnos Sciences Announces Selection of Trispecific Antibody ISB 2001 as Next Clinical Candidate for Relapsed/Refractory Multiple Myeloma

Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442

DATE: 07 July 2023 CATEGORY: PRESS RELEASE Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Trispecific Antibody, ISB 2001 The US Food and Drug Administration grants orphan drug designation to…

Continue ReadingIchnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442

Ichnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio With Astria Therapeutics

DATE: 11 Oct 2023 CATEGORY: PRESS RELEASE Ichnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio With Astria Therapeutics Astria Therapeutics is granted global rights to develop and…

Continue ReadingIchnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio With Astria Therapeutics